Breaking News

Sidley Austin Adds Life Sciences Partner

May 12, 2014

Zucker joins Palo Alto office

Sam Zucker has been named partner at Sidley Austin for the Life Sciences and Corporate Emerging Companies and Venture Capital practice groups based in Palo Alto. Mr. Zucker will focus on corporate transactions for high growth life sciences and healthcare technology companies in the U.S., Asia, and around the world.
Mr. Zucker’s main areas of expertise are M&A and financings, including joint ventures, strategic alliances, and partnerships. He has also represented companies and investors in numerous financings, including venture capital and private equity as well as IPOs, follow-on offerings, and PIPEs. Mr. Zucker has extensive experience with securities regulatory and policy matters, and advising clients’ on corporate governance and critical strategic matters.
“Sam’s proven success in handling corporate transactions for clients in the life sciences and healthcare sector will make him a valuable asset to our clients and significantly enhance the counsel we currently provide,” said Paul E. Kalb, a member of Sidley’s Executive Committee and a global coordinator of the firm’s Life Sciences practice. “We look forward to leveraging Sam’s deep knowledge and insights on behalf of our clients.”
“We are delighted to welcome a lawyer with Sam’s high level of experience leading corporate transactions for clients in the life sciences and healthcare area,” said Tom DeFilipps, managing partner of Sidley’s Palo Alto office. “Sam’s strong mix of transactional skills and sector-based knowledge will enhance our client offerings, and we look forward to him playing a key role in the expansion of our life sciences and healthcare capabilities in Northern California, as well as across the firm.”
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks